Inogen Inc. Earnings Call Highlights Transition Phase

Inogen Inc ((INGN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Inogen Inc.’s latest earnings call painted a mixed picture of a company pushing hard for growth while wrestling with near‑term financial pressure. Management highlighted solid revenue gains, robust international momentum, and encouraging early traction from new products, yet also acknowledged widening losses, softening U.S. demand, and a notable assist from foreign exchange tailwinds.

Revenue Growth and Beat

Inogen reported Q1 2026 revenue of $85.1 million, up 3.4% year over year and ahead of its own expectations. The upside was driven by a 5.7% increase in total sales revenue, supported by expanding international portable oxygen concentrator demand and favorable currency movements.

Unit Volume Expansion

Unit volumes climbed 14% versus a year ago, signalling strong end‑market demand and continued progress in placing devices with patients and providers. This growth came despite pressure in certain U.S. channels, suggesting the company is executing effectively on volume even as the mix shifts.

International Outperformance

International revenue rose to $37.7 million, an 18% year‑over‑year increase that sharply outpaced the U.S. business. Management credited deeper relationships with home medical equipment providers, success in international tenders, and expansion into Eastern Europe, Latin America, and Asia‑Pacific markets.

Gross Margin Improvement

Adjusted gross margin improved to 44.7%, up 30 basis points from 44.4% a year earlier, reflecting tangible cost efficiencies. These gains offer some cushion against rising operating expenses and demonstrate progress on the company’s profitability initiatives.

Product Launches and Clinical Momentum

The company rolled out its Aurora CPAP mask family in the U.S., backed by a 90‑day in‑home study showing patient preference, particularly for the full face mask. Inogen also launched the Rove 6 portable oxygen concentrator in Brazil and began patient enrollment in the Simeox reimbursement trial, while flagging that Aurora revenue will skew toward the back half of the year.

POC Product Differentiation

Inogen is positioning its Rove 4 and Rove 6 devices as differentiated portable oxygen concentrators with an eight‑year useful life versus five years for many rivals. Management highlighted best‑in‑class serviceability and growing outcomes data, aiming to justify premium pricing and strengthen competitive barriers.

Strong Liquidity and Capital Actions

The balance sheet remains a bright spot, with $111.5 million in cash, equivalents, marketable securities, and restricted cash, and no debt outstanding. Inogen also initiated share repurchases, buying roughly 298,000 shares for about $1.9 million, signaling confidence in its long‑term outlook despite current losses.

Reaffirmed Outlook and Revenue Guidance

The company reaffirmed full‑year 2026 revenue guidance of $366 million to $373 million, implying roughly 6% growth at the midpoint. For Q2, management guided revenue to $94 million to $97 million, or about 3.5% growth at the midpoint, and reiterated expectations for full‑year adjusted EBITDA improvement with Q2 and Q3 as the most profitable quarters.

U.S. Sales Decline and Channel Mix Headwinds

U.S. sales slipped to $34.7 million, down 5% year over year as the domestic market continues to structurally shift toward portable oxygen concentrators. This transition is weighing on direct‑to‑consumer and rental channels, creating near‑term headwinds even as the company positions itself within the evolving landscape.

Rental Business Weakness

The rental segment remained under pressure, with U.S. rental revenue falling 8% year over year to $12.7 million. Management noted an accelerated decline in net rental patients in Q1 compared with recent trends, underscoring the drag that shrinking rental volumes are exerting on overall performance.

Widening Losses and Negative EBITDA

Profitability deteriorated as GAAP net loss widened to $8.3 million from $6.2 million a year ago, while adjusted net loss increased to $4.0 million from $2.9 million. Adjusted EBITDA slipped into negative territory at minus $1.4 million, compared with roughly breakeven in the prior year period, spotlighting the cost of Inogen’s growth push.

Higher Operating Expenses from Strategic Investments

Adjusted operating expenses climbed 5.1% year over year to $43.0 million, reflecting stepped‑up strategic investment. Adjusted R&D spending rose to $4.1 million as the company accelerates clinical evidence generation and new product development, while adjusted SG&A increased to $39 million on commercial expansion and the timing of advertising.

Near‑Term Revenue Mix and Timing Risks

Management cautioned that revenue from newer products such as Aurora and Voxi 5 will be back‑half weighted, limiting their ability to offset U.S. weakness in the near term. Additionally, some of the growth tailwind in Q1 came from positive foreign exchange, leaving results somewhat exposed if currency trends reverse.

Reliance on FX Tailwind and International Execution

A meaningful portion of reported revenue growth was driven by favorable foreign exchange, which management estimated added about 460 basis points to total revenue. That dynamic means underlying growth would look smaller on a constant‑currency basis, increasing the importance of flawless execution in international markets to sustain momentum.

Forward‑Looking Guidance and Outlook

Looking ahead, Inogen is sticking with a measured but constructive outlook, anchoring on mid‑single‑digit revenue growth and improving profitability over the balance of 2026. Management expects Q2 and Q3 to be the strongest quarters for earnings, with Aurora and Voxi 5 scaling in the second half as the company continues to invest in clinical data and commercial reach.

In sum, Inogen’s earnings call framed a company in the midst of a strategic pivot, balancing solid international growth and an expanding product portfolio against U.S. softness and rising costs. Investors will be watching whether back‑half product ramps, cost discipline, and international execution can translate into the EBITDA improvement management has pledged while sustaining the company’s growth narrative.